Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 del SMARCB1 loss |
Therapy | Alisertib |
Indication/Tumor Type | rhabdoid cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 del SMARCB1 loss | rhabdoid cancer | sensitive | Alisertib | Preclinical - Cell culture | Actionable | In a preclinical study, Alisertib (MLN8237) inhibited viability of a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 in culture (PMID: 38315003). | 38315003 |
PubMed Id | Reference Title | Details |
---|---|---|
(38315003) | Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. | Full reference... |